ONTRUZANT is Samsung Bioepis’ first oncology biosimilar available in the United States ... Apr 16
Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder (MAH),... Jan 20
Samsung Bioepis’ BRENZYS™ (etanercept) becomes available in Brazil through Brazil’s public health system, Sistema Único de Saúde (SUS) Established seven years ago, Samsung ... Sep 11
-Advertisements-